to estimate total somatic inserts we searched for polya sequences that were not present in the matched normal or other normals from the same tumour batch, and were not associated with known polymorphisms.
while analysing whole genome paired-end sequencing of oesophageal adenocarcinomas to find genomic rearrangements, we identified three ways in which new mobile element insertions appear in the data, resembling translocation or insertion junctions: inserts where unique sequence has been transduced by an l <dig>  mobile element; novel inserts that are confidently, but often incorrectly, mapped by alignment software to l1s or polya tracts in the reference sequence; and a combination of these two ways, where different sequences within one insert are mapped to different loci.
samples of these candidate inserts were verified by sequencing across them or manual inspection of surrounding reads: at least  <dig> % were somatic and resembled l1-mediated events, most including l1hs sequence.
mobile elements are active in the human genome, both in the germline and cancers, where they can mutate driver genes.
somatic mobile elements insertions are abundant in these tumours, with over  <dig> % of cases having a number of novel inserts detected.
mobile elementscanceroesophageal adenocarcinomapaired-end dna sequencingissue-copyright-statementÂ© the author 2015
many of the resulting inserts were small fragments that include little or no recognisable mobile element sequence.
we found  <dig> loci in the reference genome to which sequence reads from inserts were frequently mapped, probably erroneously, by alignment software: these were either l <dig> sequence or particularly long polya runs.
we identified nine unique sequences that were transduced by neighbouring l1s, both l1s in the reference genome and l1s not present in the reference.
however, many inserts would not be detected by mapping the sequences to the reference genome, because they do not include sufficient mappable sequence.
approximately  <dig> such inserts were detected per tumour on average .
